Trial Profile
A Phase II Randomized, Double-Blind, Placebo Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody Against Hepatitis C Virus E2 Glycoprotein (MBL-HCV1) in Hepatitis C Infected Patients Undergoing Liver Transplantation.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Jun 2016
Price :
$35
*
At a glance
- Drugs MBL HCV1 (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 19 Feb 2016 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 04 Aug 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
- 04 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.